BRAF and colorectal carcinoma: Arena and colleagues tested the sensitivity to olaparib and to oxaliplatin and 5-fluorouracil (5-FU) in CRC cell lines, patient-derived organoids (PDO), and patient-derived xenografts (PDX) enriched for KRAS and BRAF mutations [83].